Editas Medicine Inc. EDIT, +0.00% priced shares for its initial public offering at the low end of the range, according to media reports late Tuesday, for what will be 2016’s first IPO. Editas will price 5.9 million shares at $16 a share, at the low end of its $16 to $18 range, to raise $94.4 million. That give Editas a market valuation of $571 million, according to Reuters. Cambridge, Mass.-based Editas develops treatments for genetic-based diseases via editing gene sequences.